Methionine Depletion with Recombinant Methioninase: in Vitro and in Vivo Efficacy Against Neuroblastoma and Its Synergism with Chemotherapeutic Drugs

Overview

Journal Int J Cancer

Specialty Oncology

Date 2008 Dec 18

PMID 19089915

Citations 20

Authors

Jian Hu

Nai-Kong V Cheung

Affiliations

Soon will be listed here.

Abstract

Methionine starvation can modulate gene methylation, cell cycle transition and pathways related to survival following DNA damage. Methionine depletion by recombinant methioninase (rMETase) may have in vitro and in vivo efficacy against neuroblastoma (NB), especially when combined with chemotherapeutic drugs. rMETase from Pseudomonas putida was produced in Escherichia coli and purified by ion-exchange chromatography. rMETase alone inhibited the proliferation of 15/15 NB cell lines in vitro. Among these 15 cell lines, only 66N demonstrated rMETase-induced apoptosis. rMETase alone suppressed LAN-1 and NMB-7 xenografts (p < 0.01) and no toxicities were noted other than reversible weight loss. In vitro efficacy experiments combining rMETase and chemotherapeutic agents were carried out using SK-N-LD and SK-N-BE (1)N established at diagnosis, as well as LAN-1, SK-N-BE (2)C and NMB-7 established at relapse. Microtubule depolymerization agents including vincristine, vinorelbine, vinblatine and mebendazole showed synergism when tested in combination with rMETase in all 5 cell lines. Among DNA damaging agents, synergy with rMETase was observed only in cell lines established at diagnosis and not at relapse. Cell cycle analysis showed that rMETase arrested G2 phase and not M phase. In vivo efficacy experiments using LAN-1 and NMB-7 xenografts showed that rMETase rendered vincristine more effective than vincristine alone in tumor growth suppression (p < 0.001). In conclusion, methionine depletion inhibited NB proliferation and arrested tumor cells at G2 phase. rMETase synergized with microtubule depolymerization agents. Moreover, synergism between rMETase and DNA damaging agents was dependent on whether cell lines were established at diagnosis or at relapse.

Citing Articles

Human arginase I: a potential broad-spectrum anti-cancer agent.

Anakha J, Prasad Y, Sharma N, Pande A 3 Biotech. 2023; 13(5):159.

PMID: 37152001 PMC: 10156892. DOI: 10.1007/s13205-023-03590-3.

Pharmacokinetic/pharmacodynamic model of a methionine starvation based anti-cancer drug.

Eymard N, Bessonov N, Volpert V, Kurbatova P, Gueyffier F, Nony P Med Biol Eng Comput. 2023; 61(7):1697-1722.

PMID: 36882575 DOI: 10.1007/s11517-023-02786-2.

Predictive markers for efficiency of the amino-acid deprivation therapies in cancer.

Pokrovsky V, Qoura L, Morozova E, Bunik V Front Med (Lausanne). 2022; 9:1035356.

PMID: 36405587 PMC: 9669297. DOI: 10.3389/fmed.2022.1035356.

Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome.

Golbourn B, Halbert M, Halligan K, Varadharajan S, Krug B, Mbah N Nat Cancer. 2022; 3(5):629-648.

PMID: 35422502 PMC: 9551679. DOI: 10.1038/s43018-022-00348-3.

Amino Acid Degrading Enzymes and Autophagy in Cancer Therapy.

Wang Z, Xie Q, Zhou H, Zhang M, Shen J, Ju D Front Pharmacol. 2021; 11:582587.

PMID: 33510635 PMC: 7836011. DOI: 10.3389/fphar.2020.582587.

References

Stern P, Hoffman R . Enhanced in vitro selective toxicity of chemotherapeutic agents for human cancer cells based on a metabolic defect. J Natl Cancer Inst. 1986; 76(4):629-39. DOI: 10.1093/jnci/76.4.629. View

Sun X, Tan Y, Yang Z, Li S, Hoffman R . A rapid HPLC method for the measurement of ultra-low plasma methionine concentrations applicable to methionine depletion therapy. Anticancer Res. 2005; 25(1A):59-62. View

Tan Y, Xu M, Tan X, Wang X, Saikawa Y, Nagahama T . Overexpression and large-scale production of recombinant L-methionine-alpha-deamino-gamma-mercaptomethane-lyase for novel anticancer therapy. Protein Expr Purif. 1997; 9(2):233-45. DOI: 10.1006/prep.1996.0700. View

Kokkinakis D, von Wronski M, Vuong T, Brent T, Schold Jr S . Regulation of O6-methylguanine-DNA methyltransferase by methionine in human tumour cells. Br J Cancer. 1997; 75(6):779-88. PMC: 2063394. DOI: 10.1038/bjc.1997.141. View

Moephuli S, KLEIN N, Baldwin M, Krider H . Effects of methionine on the cytoplasmic distribution of actin and tubulin during neural tube closure in rat embryos. Proc Natl Acad Sci U S A. 1997; 94(2):543-8. PMC: 19549. DOI: 10.1073/pnas.94.2.543. View

Yoshioka T, Wada T, Uchida N, Maki H, Yoshida H, Ide N . Anticancer efficacy in vivo and in vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase. Cancer Res. 1998; 58(12):2583-7. View

Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View

Thompson J, George E, Poquette C, Cheshire P, Richmond L, de Graaf S . Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res. 1999; 5(11):3617-31. View

Kokkinakis D . Methionine-stress: a pleiotropic approach in enhancing the efficacy of chemotherapy. Cancer Lett. 2006; 233(2):195-207. DOI: 10.1016/j.canlet.2005.02.034. View

10.

Harris S, Scott J, Brown J, Charlton P, Mistry P . Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma. Anticancer Drugs. 2005; 16(9):945-51. DOI: 10.1097/01.cad.0000176499.17939.56. View

11.

Ramirez T, Garcia-Montalvo V, Wise C, Cea-Olivares R, Poirier L, Herrera L . S-adenosyl-L-methionine is able to reverse micronucleus formation induced by sodium arsenite and other cytoskeleton disrupting agents in cultured human cells. Mutat Res. 2003; 528(1-2):61-74. DOI: 10.1016/s0027-5107(03)00099-x. View

12.

Lishko V, Lishko O, Hoffman R . Depletion of serum methionine by methioninase in mice. Anticancer Res. 1993; 13(5A):1465-8. View

13.

Cellarier E, Durando X, Vasson M, Farges M, Demiden A, Maurizis J . Methionine dependency and cancer treatment. Cancer Treat Rev. 2003; 29(6):489-99. DOI: 10.1016/s0305-7372(03)00118-x. View

14.

Iolascon A, Borriello A, Giordani L, Cucciolla V, Moretti A, Monno F . Caspase 3 and 8 deficiency in human neuroblastoma. Cancer Genet Cytogenet. 2003; 146(1):41-7. DOI: 10.1016/s0165-4608(03)00125-0. View

15.

Wagner L, McLendon R, Yoon K, Weiss B, Billups C, Danks M . Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res. 2007; 13(18 Pt 1):5418-25. DOI: 10.1158/1078-0432.CCR-07-0418. View

16.

Livingston D, Silver D . Cancer: crossing over to drug resistance. Nature. 2008; 451(7182):1066-7. DOI: 10.1038/4511066a. View

17.

Breillout F, Antoine E, Poupon M . Methionine dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst. 1990; 82(20):1628-32. DOI: 10.1093/jnci/82.20.1628. View

18.

Goseki N, Yamazaki S, Shimojyu K, Kando F, Maruyama M, Endo M . Synergistic effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on human gastric cancer: a randomized, prospective clinical trial. Jpn J Cancer Res. 1995; 86(5):484-9. PMC: 5920843. DOI: 10.1111/j.1349-7006.1995.tb03082.x. View

19.

Kokkinakis D, Hoffman R, Frenkel E, Wick J, Han Q, Xu M . Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res. 2001; 61(10):4017-23. View

20.

Hoffman R, Jacobsen S . Reversible growth arrest in simian virus 40-transformed human fibroblasts. Proc Natl Acad Sci U S A. 1980; 77(12):7306-10. PMC: 350491. DOI: 10.1073/pnas.77.12.7306. View